XNCR: Xencor, Inc. Stock

by  •  • Comments Off on XNCR: Xencor, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,337.36
Enterprise Value ($M) 1,323.31
Book Value ($M) 720.90
Book Value / Share 10.30
Price / Book 1.86
NCAV ($M) 310.59
NCAV / Share 4.44
Price / NCAV 4.31

Profitability (mra)
Return on Invested Capital (ROIC) -0.25
Return on Assets (ROA) -0.21
Return on Equity (ROE) -0.30

Liquidity (mrq)
Quick Ratio 6.23
Current Ratio 6.23

Balance Sheet (mrq) ($M)
Current Assets 573.33
Assets 983.63
Liabilities 262.74
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A EcoR1 Capital, LLC 9.40 27.20
11-14 13G/A Price T Rowe Associates Inc /md/ 5.60 12.58
11-12 13G/A Primecap Management Co/ca/ 13.08 2.65
11-08 13G/A BlackRock, Inc. 15.80 0.00
10-18 13G/A State Street Corp 4.50 -6.24
02-16 13G/A T. Rowe Price Investment Management, Inc. 2.20 0.00
02-13 13G/A Vanguard Group Inc 11.12 1.73
02-09 13G/A Fmr Llc 4.21 -33.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-02-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSITION REPORT PURSUANT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-15 125,860 476,799 26.40
2025-01-14 86,246 432,709 19.93
2025-01-13 108,838 500,755 21.73
2025-01-10 98,001 571,949 17.13

(click for more detail)

Similar Companies
VRCA – Verrica Pharmaceuticals Inc. WVE – Wave Life Sciences Ltd.
XENE – Xenon Pharmaceuticals Inc. XOMA – XOMA Royalty Corporation


Financial data and stock pages provided by
Fintel.io